Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPPHIRE: sitravatinib + nivolumab versus docetaxel in previously treated advanced non-squamous NSCLC
2019-001043-41Phase 3Completed
- Sponsor
- Mirati Therapeutics
- Start
- May 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Non-small cell lung cancer (NS-NSCLC) comparing sitravatinib + nivolumab with docetaxel (2 arms). Primary endpoint: Overall Survival. Started May 2020; status: completed.
02
Drugs
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2019-001043-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001043-41.